Prevention of Cardiovascular Disease in Patients with Psoriasis and Psoriatic Arthritis: Bridging the Evidence to Practice Gap for Statins



Patients with psoriasis and psoriatic arthritis have an increased risk of cardiovascular mortality, but are less likely to have traditional cardiovascular risk factors identified and managed. This is a major evidence to practice gap. To improve the prevention of cardiovascular disease in patients with psoriatic disease, NHLBI, in conjunction with the University of Pennsylvania School of Medicine are hosting a virtual meeting on Friday, April 9, 2021.

The meeting will bring together a diverse set of experts, both from the intramural and extramural communities to discuss this evidence to practice gap, and will present new data that we have developed through the National Psoriasis Foundation’s Psoriasis Prevention Initiative to understand why patients with psoriatic disease are under-screened for dyslipidemia and why they are less likely to take statins when eligible. Additionally, the goal of the meeting is to get input from dermatologists, rheumatologists, cardiologists, implementation scientists, patient advocates and other stakeholders so we may optimize the design of our trial.

This free, virtual meeting will be hosted on Zoom. A reminder will be sent prior to the meeting that will include the URL.

Follow the conversation on Twitter via #CP3Meeting.

Meeting Agenda


  • Nehal Mehta, MD, MSCE, FAHA, Lasker Senior Investigator, Chief, Lab of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, NIH (@NehalMehtaMD)
  • Joel Gelfand, MD, MSCE, Professor of Dermatology and of Epidemiology, Vice Chair of Clinical Research and Medical Director, Dermatology Clinical Studies Unit, Director, Psoriasis and Phototherapy Treatment Center, University of Pennsylvania Perelman School of Medicine (@DrJoelGelfand)